PMID- 25993179
OWN - NLM
STAT- MEDLINE
DCOM- 20160218
LR  - 20180827
IS  - 1548-8756 (Electronic)
IS  - 1548-8748 (Linking)
DP  - 2015
TI  - Challenging the treatment paradigm for advanced renal cell carcinoma: a review of 
      systemic and localized therapies.
PG  - e239-47
LID - 10.14694/EdBook_AM.2015.35.e239 [doi]
AB  - The current standard of care for the management of advanced renal cell carcinoma 
      (RCC) revolves around systemic therapy with molecularly targeted agents. Over the 
      last decade, a total of seven targeted drugs have been approved but, altogether, 
      only exploit two molecular targets in this disease: the vascular endothelial 
      growth factor (VEGF) axis and the mammalian target of rapamycin (mTOR). 
      Introduction of these agents has markedly improved outcomes compared with those 
      in the cytokine era, yet comparatively little progress has been made since 
      registration of the first targeted therapeutics occurred 10 years ago. In this 
      article, we review efforts to improve on this current treatment paradigm. We 
      discuss novel targets in this disease and corresponding new agents under 
      investigation. The article dedicates particular attention to targeted 
      immunotherapeutics, which are rapidly emerging as a new category of interest in 
      this disease. Last, we review current data supporting the use of surgical 
      interventions to improve outcomes in patients with metastatic disease.
FAU - Bex, Axel
AU  - Bex A
AD  - From the Netherlands Cancer Institute, Amsterdam, Netherlands; The Royal Marsden 
      NHS Foundation Trust, London, United Kingdom; Memorial Sloan Kettering Cancer 
      Center, New York, NY; Weill Cornell Medical College, New York, NY.
FAU - Larkin, James
AU  - Larkin J
AD  - From the Netherlands Cancer Institute, Amsterdam, Netherlands; The Royal Marsden 
      NHS Foundation Trust, London, United Kingdom; Memorial Sloan Kettering Cancer 
      Center, New York, NY; Weill Cornell Medical College, New York, NY.
FAU - Voss, Martin
AU  - Voss M
AD  - From the Netherlands Cancer Institute, Amsterdam, Netherlands; The Royal Marsden 
      NHS Foundation Trust, London, United Kingdom; Memorial Sloan Kettering Cancer 
      Center, New York, NY; Weill Cornell Medical College, New York, NY.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am Soc Clin Oncol Educ Book
JT  - American Society of Clinical Oncology educational book. American Society of 
      Clinical Oncology. Annual Meeting
JID - 101233985
SB  - IM
MH  - Carcinoma, Renal Cell/metabolism/pathology/*therapy
MH  - Humans
MH  - Kidney Neoplasms/metabolism/pathology/*therapy
MH  - Molecular Targeted Therapy
MH  - Randomized Controlled Trials as Topic
EDAT- 2015/05/21 06:00
MHDA- 2016/02/19 06:00
CRDT- 2015/05/21 06:00
PHST- 2015/05/21 06:00 [entrez]
PHST- 2015/05/21 06:00 [pubmed]
PHST- 2016/02/19 06:00 [medline]
AID - 0011500e239 [pii]
AID - 10.14694/EdBook_AM.2015.35.e239 [doi]
PST - ppublish
SO  - Am Soc Clin Oncol Educ Book. 2015:e239-47. doi: 10.14694/EdBook_AM.2015.35.e239.